^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Steroid receptor agonist

5d
Case Report: Niraparib-abiraterone in HRR-mutated metastatic castration-resistant prostate cancer: clinical insights from five cases. (PubMed, Front Oncol)
Combination therapy with the PARP inhibitor niraparib and the androgen-receptor inhibitor abiraterone acetate plus prednisone (AAP) has recently shown improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations, particularly BRCA1/2, in the phase III MAGNITUDE trial. However, the very small sample size, retrospective design, and absence of standardized rPFS assessment limit generalizability. These findings are primarily hypothesis-generating but align with prospective trial results and underscore the heterogeneity of HRR-mutated mCRPC, highlighting the need for individualized therapeutic strategies.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2)
|
Zejula (niraparib) • abiraterone acetate • prednisone
5d
New trial
|
dexamethasone injection
6d
The Effect of Dexamethasone Administration Route in Pediatric Brachial Plexus Block (clinicaltrials.gov)
P4, N=90, Recruiting, Poznan University of Medical Sciences | Trial completion date: Feb 2026 --> Jun 2026 | Trial primary completion date: Dec 2025 --> May 2026
Trial completion date • Trial primary completion date
|
dexamethasone injection
7d
Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial. (PubMed, World J Urol)
In this phase II single-arm study, olaparib plus abiraterone and ADT showed preliminary activity and a manageable safety profile in patients with HRR-mutated mHSPC, but these findings need to be confirmed in larger phase III studies.
P2 data • Journal • PARP Biomarker
|
HRD (Homologous Recombination Deficiency)
|
Lynparza (olaparib) • abiraterone acetate • prednisone
7d
Subcarinal Mass: An Unusual Presentation of Granulomatosis With Polyangiitis. (PubMed, Am J Case Rep)
She was treated with prednisone and rituximab and had significant clinical improvement at the time of discharge. This case details an unusual presentation of GPA as a subcarinal mass. It highlights the importance of considering GPA as a possible diagnosis for patients with constitutional symptoms, mediastinal mass, and necrotizing granulomatous inflammation on pathology.
Journal
|
PRSS3 (Serine Protease 3)
|
Rituxan (rituximab) • prednisone
7d
REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) (clinicaltrials.gov)
P3, N=50, Active, not recruiting, The Hospital for Sick Children | Recruiting --> Active, not recruiting | Trial completion date: Nov 2026 --> Feb 2027
Enrollment closed • Trial completion date
|
prednisone • methylprednisolone sodium succinate
7d
Trial initiation date • HEOR
|
dexamethasone injection
11d
Enrollment open
|
prednisone • methylprednisolone sodium succinate
13d
Ventilation and Perfusion in Asthmatics (clinicaltrials.gov)
P4, N=40, Recruiting, University of Miami | Not yet recruiting --> Recruiting
Enrollment open
16d
Prednisone for CRPS in Distal Radius Fracture (clinicaltrials.gov)
P=N/A, N=40, Recruiting, University of British Columbia | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jan 2026 --> May 2027
Trial completion date • Trial primary completion date
|
prednisone
16d
Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant (clinicaltrials.gov)
P=N/A, N=236, Active, not recruiting, AbbVie | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
Trial completion date • Trial primary completion date